AI Portfolio Summary
In 2025 Q4, Frazier Life Sciences Management, L.P. maintained a portfolio of 52 distinct positions. The most significant new addition to the portfolio was RAPT THERAPEUTICS IN, which now represents 0.89% of the total fund value. They heavily accumulated shares in NEWAMSTERDAM PHARMA , increasing their position by 1.4%. Conversely, Frazier Life Sciences Management, L.P. completely exited their position in VERONA PHARMA PLC.
Total Positions
52
Quarter
2025 Q4
Top Holding
NAMS (16.0%)
Top 10 Concentration
71.0%
Turnover Rate
23.4%
Sector HHI
0.18
Items per page:
1-25 of 52
| Stock | History | Sector / Type | Port % | Prev % | Rank / Prev | Conviction | Change | % Change | Influence | Shares | Mkt Value | Avg Cost | Price Held | 1st Owned | Source | Source Date | Date Reported |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
NAMS
NEWAMSTERDAM PH...
|
Healthcare | 15.96% | 14.23% |
#1
1
Prev: #2
|
8.4 | 241,818 | 1.4% |
P
S
|
16,943,774 | $594,387,592 | 2022 Q4 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
MIRM
MIRUM PHARMACEU...
|
Healthcare | 14.42% | 14.93% |
#2
1
Prev: #1
|
5.8 | no change | no change |
P
S
|
6,795,121 | $536,746,608 | 2022 Q1 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
ARQT
ARCUTIS BIOTHER...
|
Healthcare | 7.70% | 5.58% |
#3
2
Prev: #5
|
3.1 | no change | no change |
P
S
|
9,874,511 | $286,755,799 | 2022 Q1 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
BBIO
BRIDGEBIO PHARM...
|
Healthcare | 7.28% | 5.98% |
#4
Prev: #4
|
2.9 | -299,900 | -7.8% |
P
S
|
3,545,557 | $271,199,655 | 2023 Q1 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
MBX
MBX BIOSCIENCES...
|
Healthcare | 5.64% | 3.49% |
#5
4
Prev: #9
|
2.3 | no change | no change |
P
S
|
6,652,013 | $209,804,490 | 2024 Q3 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
PHAT
PHATHOM PHARMAC...
|
Healthcare | 5.55% | 4.40% |
#6
Prev: #6
|
2.2 | no change | no change |
P
S
|
12,466,489 | $206,819,053 | 2022 Q1 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
MAZE
MAZE THERAPEUTI...
|
Healthcare | 5.08% | 3.55% |
#7
1
Prev: #8
|
2.0 | no change | no change |
P
S
|
4,567,274 | $189,222,162 | 2025 Q1 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
TRVI
TREVI THERAPEUT...
|
Healthcare | 3.45% | 2.81% |
#8
3
Prev: #11
|
1.4 | no change | no change |
P
S
|
10,259,409 | $128,447,801 | 2022 Q2 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
KRYS
KRYSTAL BIOTECH...
|
Healthcare | 3.23% | 3.64% |
#9
2
Prev: #7
|
1.4 | -200,000 | -29.1% |
P
S
|
488,460 | $120,424,928 | 2022 Q1 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
IRON
DISC MEDICINE I...
|
Healthcare | 2.69% | 2.85% |
#10
Prev: #10
|
1.1 | -178,534 | -12.4% |
P
S
|
1,260,000 | $100,056,600 | 2023 Q2 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
ERAS
ERASCA INC
|
Healthcare | 2.27% | 1.48% |
#11
5
Prev: #16
|
0.9 | no change | no change |
P
S
|
22,729,436 | $84,553,502 | 2024 Q2 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
KALV
KALVISTA PHARMA...
|
Healthcare | 2.19% | 1.84% |
#12
1
Prev: #13
|
0.9 | no change | no change |
P
S
|
5,039,867 | $81,393,852 | 2022 Q1 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
PVLA
PALVELLA THERAP...
|
Healthcare | 2.03% | 1.36% |
#13
6
Prev: #19
|
0.8 | no change | no change |
P
S
|
722,400 | $75,613,608 | 2024 Q4 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
RNA
AVIDITY BIOSCIE...
|
Healthcare | 1.90% | 0.82% |
#14
13
Prev: #27
|
2.9 | 358,125 | 57.3% |
P
S
|
983,125 | $70,912,806 | 2022 Q4 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
RVMD
REVOLUTION MEDI...
|
Healthcare | 1.71% | 1.40% |
#15
3
Prev: #18
|
0.7 | -200,000 | -20.1% |
P
S
|
797,455 | $63,517,291 | 2023 Q1 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
DYN
DYNE THERAPEUTI...
|
Healthcare | 1.66% | 1.03% |
#16
5
Prev: #21
|
2.7 | 434,977 | 16.0% |
P
S
|
3,153,082 | $61,674,284 | 2023 Q4 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
TARS
TARSUS PHARMACE...
|
Healthcare | 1.60% | 2.08% |
#17
5
Prev: #12
|
0.8 | -438,883 | -37.6% |
P
S
|
728,644 | $59,661,371 | 2022 Q1 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
SVRA
SAVARA INC
|
Healthcare | 1.60% | 1.23% |
#18
2
Prev: #20
|
0.7 | -1,600,000 | -14.0% |
P
S
|
9,862,301 | $59,469,675 | 2023 Q3 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
CYTK
CYTOKINETICS IN...
|
Healthcare | 1.60% | 1.47% |
#19
2
Prev: #17
|
2.7 | 44,197 | 5.0% |
P
S
|
934,642 | $59,387,153 | 2025 Q2 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
ABVX
ABIVAX SA
|
Healthcare | 1.37% | 0.96% |
#20
2
Prev: #22
|
0.5 | no change | no change |
P
S
|
378,300 | $51,015,647 | 2025 Q3 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
LXEO
LEXEO THERAPEUT...
|
Healthcare | 1.18% | 0.88% |
#21
4
Prev: #25
|
0.5 | no change | no change |
P
S
|
4,424,725 | $43,937,519 | 2024 Q3 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
AGIO
AGIOS PHARMACEU...
|
Healthcare | 0.94% | 1.54% |
#22
7
Prev: #15
|
0.4 | no change | no change |
P
S
|
1,279,754 | $34,834,904 | 2023 Q3 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
ACAD
ACADIA PHARMACE...
|
Healthcare | 0.93% | 0.39% |
#23
13
Prev: #36
|
2.7 | 683,361 | 111.3% |
P
S
|
1,297,198 | $34,648,159 | 2022 Q3 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
ZLAB
ZAI LAB LTD
|
Healthcare | 0.90% | 1.65% |
#24
10
Prev: #14
|
2.4 | 275,000 | 16.9% |
P
S
|
1,902,320 | $33,556,925 | 2025 Q1 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
RAPT
RAPT THERAPEUTI...
|
Healthcare | 0.89% | — |
#25
Prev: #—
|
2.4 | 983,333 | no change |
NEW
|
983,333 | $33,305,489 | 2025 Q4 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
VRNA
VERONA PHARMA P...
|
Unknown | 0.00% | 10.82% |
Sold All 😨
(Was: #3) |
0.3 | -3,383,950 | -100.0% |
CLOSED
|
— | $— | 2022 Q3 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
RARE
ULTRAGENYX PHAR...
|
Healthcare | 0.00% | 0.89% |
Sold All 😨
(Was: #24) |
0.3 | -983,715 | -100.0% |
CLOSED
|
— | $— | 2024 Q2 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
MREO
MEREO BIOPHARMA...
|
Healthcare | 0.00% | 0.58% |
Sold All 😨
(Was: #30) |
0.3 | -9,440,112 | -100.0% |
CLOSED
|
— | $— | 2024 Q2 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
AKRO
AKERO THERAPEUT...
|
Healthcare | 0.00% | 0.52% |
Sold All 😨
(Was: #31) |
0.3 | -366,784 | -100.0% |
CLOSED
|
— | $— | 2025 Q2 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
PCVX
VAXCYTE INC
|
Healthcare | 0.00% | 0.51% |
Sold All 😨
(Was: #32) |
0.3 | -474,405 | -100.0% |
CLOSED
|
— | $— | 2022 Q1 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
JBIO
JADE BIOSCIENCE...
|
Healthcare | 0.00% | 0.37% |
Sold All 😨
(Was: #37) |
0.3 | -1,413,280 | -100.0% |
CLOSED
|
— | $— | 2025 Q2 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
ASMB
ASSEMBLY BIOSCI...
|
Healthcare | 0.00% | 0.35% |
Sold All 😨
(Was: #38) |
0.3 | -456,249 | -100.0% |
CLOSED
|
— | $— | 2025 Q3 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
ADVM
ADVERUM BIOTECH...
|
Healthcare | 0.00% | 0.28% |
Sold All 😨
(Was: #39) |
0.3 | -2,077,431 | -100.0% |
CLOSED
|
— | $— | 2024 Q1 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
ENGN
ENGENE HOLDINGS...
|
Healthcare | 0.00% | 0.24% |
Sold All 😨
(Was: #42) |
0.3 | -1,157,380 | -100.0% |
CLOSED
|
— | $— | 2025 Q3 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
MGNX
MACROGENICS INC
|
Healthcare | 0.00% | 0.16% |
Sold All 😨
(Was: #44) |
0.3 | -3,175,665 | -100.0% |
CLOSED
|
— | $— | 2022 Q3 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
SLN
SILENCE THERAPE...
|
Healthcare | 0.00% | 0.15% |
Sold All 😨
(Was: #45) |
0.3 | -970,130 | -100.0% |
CLOSED
|
— | $— | 2022 Q1 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
N/A
CRESCENT BIOPHA...
|
—
|
Unknown | 0.00% | 0.10% |
Sold All 😨
(Was: #47) |
0.3 | -272,951 | -100.0% |
CLOSED
|
— | $— | — | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) |
Showing 1-25 of 52 holdings